Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
2.
Cells Tissues Organs ; 197(5): 384-98, 2013.
Article in English | MEDLINE | ID: mdl-23485626

ABSTRACT

INTRODUCTION: Adipose tissue-derived stem cells (ASCs) have become the primary focus of tissue engineering research. To understand their functions and behavior in in vitro and in vivo models, it is mandatory to track the implanted cells and distinguish them from the resident or host cells. A common labeling method is the use of fluorescent dyes, e.g. the lipophilic carbocyanine dye, DiI. This study aimed to analyze potential DNA damage, toxicity and impairment of the functional properties of human ASCs after labeling with DiI. METHODS: Cytotoxicity was measured using the MTT assay and DNA damage was determined by means of the comet assay. Potential apoptotic effects were determined using the annexin V-propidium iodide test. Differentiation potential was evaluated by trilineage differentiation procedures in labeled and unlabeled ASCs. Proliferation as well as migration capability was analyzed, and the duration and stability of DiI labeling in ASCs during in vitro expansion was observed over a period of 35 days. RESULTS: DiI labeling did not cause genotoxic effects 15, or 30 min or 24 h after the labeling procedure, and there were no cytotoxic effects until 72 h afterwards. No impairment of proliferation or migration capability or differentiation potential could be determined. However, after 35 days, only 37% of labeled cells could be detected using the fluorescence microscope, which indicates a decrease in staining stability during in vitro expansion. CONCLUSION: DiI is a convenient method for ASCs labeling which causes no toxic effects and does not impair the proliferation, migration or differentiation potential of ASCs after the labeling procedure.


Subject(s)
Adipose Tissue/cytology , Carbocyanines/metabolism , Carbocyanines/toxicity , DNA Damage , Stem Cells/cytology , Annexin A5/metabolism , Cell Death/drug effects , Cell Differentiation/drug effects , Cell Lineage/drug effects , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Comet Assay , Humans , Phenotype , Propidium/metabolism , Staining and Labeling , Stem Cells/drug effects , Stem Cells/metabolism , Trypan Blue/metabolism
3.
Toxicol Lett ; 218(3): 207-14, 2013 Apr 26.
Article in English | MEDLINE | ID: mdl-23410960

ABSTRACT

Various hypotheses on the origin of cancer stem cells (CSCs) exist, including that CSCs develop from transformed human bone marrow mesenchymal stem cells (hBMSC). Since the polyether antibiotic salinomycin selectively kills CSCs, the present study aims to elucidate the effects of salinomycin on normal hBMSC. The immunophenotype of hBMSC after salinomycin exposure was observed by flow cytometry. The multi-differentiation capacity of hBMSC was evaluated by Oil Red O and van Kossa staining. Cytotoxic effects of salinomycin were monitored by the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT) assay. Furthermore, spheroid formation and migration capacity were assessed. There were no differences in the immunophenotype and multi-differentiation capacity of hBMSC induced by salinomycin treatment. Cytotoxic effects were observed at concentrations of 30 µM and above. Neither the migration capability nor the ability to form spheroids was affected. Essential functional properties of hBMSC were unaffected by salinomycin. However, dose-dependent cytotoxicity effects could be observed. Overall, low dose salinomycin showed no negative effects on hBMSC. Since mesenchymal stem cells from various sources respond differently, further in vitro studies are needed to clarify the effect of salinomycin on tissue-specific stem cells.


Subject(s)
Bone Marrow Cells/drug effects , Mesenchymal Stem Cells/drug effects , Pyrans/toxicity , Bone Marrow Cells/immunology , Bone Marrow Cells/pathology , Cell Differentiation/drug effects , Cell Line , Cell Movement/drug effects , Cell Shape/drug effects , Cell Survival/drug effects , Dose-Response Relationship, Drug , Flow Cytometry , Humans , Immunophenotyping/methods , Mesenchymal Stem Cells/immunology , Mesenchymal Stem Cells/pathology
4.
Strahlenther Onkol ; 189(1): 62-7, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23161119

ABSTRACT

BACKGROUND AND PURPOSE: Osteopontin (OPN) is a multifunctional protein overexpressed in many cancers and is involved in tumor progression and metastasis. In lung cancer, elevated OPN expression is associated with an unfavorable prognosis. Therefore, inhibition of OPN is an attractive approach for improving survival. MATERIALS AND METHODS: We used siRNA to specifically downregulate OPN expression in A549 lung cancer cells. OPN silencing was evaluated with quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for mRNA levels and with Western blotting for protein levels. Effects on cell proliferation were measured by cell counting. The influence on tumor cell migration was detected using a modified Boyden chamber. Changes in cell cycle distribution were assessed by flow cytometry. Using the colony formation assay, we determined changes in radiosensitivity. RESULTS: A specific and effective downregulation of OPN expression was detected in both RNA and protein levels. Cell proliferation and cell migration were significantly reduced by OPN silencing after 24 h and the effects were further increased by the addition of irradiation. The cell cycle distribution showed a reduction in S phase and an increase in cells arrested in both G(0)/G(1) and G(2)/M phases. Specific enhancement of radiosensitivity was clearly shown after OPN knockdown. CONCLUSION: The combination of OPN silencing and irradiation showed a synergistic effect leading to reduced cell survival.


Subject(s)
Adenocarcinoma/genetics , Adenocarcinoma/pathology , Cell Movement/genetics , Cell Survival/genetics , Gene Silencing , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Osteopontin/genetics , Blotting, Western , Cell Cycle/radiation effects , Cell Proliferation , Disease Progression , Dose-Response Relationship, Radiation , Down-Regulation/genetics , Gene Expression Regulation, Neoplastic/genetics , Humans , RNA, Small Interfering/genetics , Real-Time Polymerase Chain Reaction , Transfection , Tumor Cells, Cultured/pathology , Tumor Stem Cell Assay
5.
Oncogene ; 20(11): 1307-17, 2001 Mar 15.
Article in English | MEDLINE | ID: mdl-11313875

ABSTRACT

Neuroblastoma (NB) cells reportedly accumulate wild-type p53 exclusively in the cytoplasm. However, immunofluorescence assays with five different antibodies showed that p53 accumulates in the nucleus of up to 10% of NB cells. PAb1801 detected cytoplasmic 'punctate structures' which were also found in p53-null cells, rendering this antibody unsuitable for p53 detection. A comparison of DO-1 and PAb1801 staining in NB tissue sections confirmed the results obtained with NB cells. Nuclear accumulation of p53 was induced in NB cells using substances which disturb p53's tertiary structure at its zinc finger motif, or by treatment with mitomycin C. Constitutive nuclear accumulation was observed in an SK-N-SH variant, AW-1, which has a point mutation in p53 at Cys176>Ser, disturbing the same motif. Even though p53 showed DNA-binding capability after mitomycin C treatment of NB cells, the target gene products MDM2 and p21(WAF1,CIP1,SDI1) were not synthesized and no p53 transactivating activity measured in a reporter gene assay. Therefore we suggest that p53 in NB cells might be predominantly in a conformation refractory to integration into the transcriptional complex, resulting in at least partial transcriptional inactivity, hyperactive nuclear export and resistance to degradation by exogenously expressed MDM2.


Subject(s)
Cell Transformation, Neoplastic , Neuroblastoma/metabolism , Transcription, Genetic , Tumor Suppressor Protein p53/metabolism , Animals , Cell Compartmentation , Cell Nucleus/metabolism , Humans , Mice , Precipitin Tests , Protein Conformation , Protein Transport , Sequence Analysis, DNA , Tumor Cells, Cultured , Tumor Suppressor Protein p53/genetics
6.
Int J Oncol ; 18(2): 281-6, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11172593

ABSTRACT

Human SV40-transformed cells contain high levels of stabilized p53 of which only a fraction is complexed with the SV40 large tumor antigen (T-antigen). This raises the question whether the p53 which is not complexed with T-antigen retains some biological activity. Two human SV40-transformed cell lines, BEAS and SV80, were investigated. A significant level of constitutive cognate-sequence-specific DNA-binding of p53 was detected by electrophoretic mobility shift assay (EMSA) of cell extracts. Upon DNA damage by treatment with mitomycin C the DNA-binding activity was increased, as known for cells with wild-type p53. However, in both cell lines, before and after DNA damage, p53 was not able to transactivate a target gene as shown by reporter gene assay. Hence, the capability of p53 to bind its cognate sequence is a prerequisite but no proof of p53 transactivating activity. Nuclear p53 levels were not further increased after mitomycin C treatment, occasionally rather slightly decreased, often accompanied by an even larger decrease in amount of T-antigen. In conclusion, SV40-transformation of human cells has caused a loss of essential features of wild-type p53 activity, even in that fraction of p53 not in physical complex with SV40 T-antigen.


Subject(s)
Antigens, Polyomavirus Transforming/metabolism , DNA Damage/physiology , Tumor Suppressor Protein p53/metabolism , Animals , Cell Line/drug effects , Cell Line/metabolism , Cell Line, Transformed , Cross-Linking Reagents/pharmacology , DNA Damage/drug effects , Humans , Mice , Mice, Inbred C57BL , Mitomycin/pharmacology , Simian virus 40/metabolism
7.
Oncogene ; 15(6): 669-76, 1997 Aug 07.
Article in English | MEDLINE | ID: mdl-9264407

ABSTRACT

Stimulation of NIH3T3 cells with platelet-derived growth factor (PDGF)-BB enhances expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and a key mediator of tumor angiogenesis. Here, we identified cis-acting VEGF promoter elements and trans-acting factors which are involved in PDGF-stimulated VEGF expression. By 5'-deletion and transient transfection analysis, a G + C-rich region at -85 to -50 of the human VEGF promoter was shown to be necessary and sufficient for both PDGF inducible and basal expression. The region contains three potential recognition sites for Sp1 transcription factors, which overlap with two Egr-1 sites. Mutations that abolish the ability of Sp1 to interact with the VEGF promoter element also abrogate expression induced by PDGF. Mutations of the potential Egr-1 binding sites did not affect PDGF responsiveness. Gel shift and antibody supershift analyses showed that Sp1 and Sp3 interact constitutively with the VEGF promoter element. Our data strongly suggest that enhanced VEGF gene expression in PDGF-induced NIH3T3 cells is mediated by Sp1 and/or Sp3 transcription factors bound to the -85 to -50 promoter region of the VEGF gene.


Subject(s)
Endothelial Growth Factors/genetics , Immediate-Early Proteins , Lymphokines/genetics , Promoter Regions, Genetic , Sp1 Transcription Factor/genetics , Transcription Factors , 3T3 Cells , Animals , Antibodies, Blocking/immunology , Base Composition , Cells, Cultured , Cloning, Molecular , DNA-Binding Proteins/genetics , Early Growth Response Protein 1 , Gene Expression Regulation, Neoplastic , Humans , Luciferases/genetics , Mice , Platelet-Derived Growth Factor/pharmacology , Retroviridae Proteins, Oncogenic/genetics , Sequence Deletion , Sp1 Transcription Factor/immunology , TATA Box , Thymidine Kinase/genetics , Trans-Activators/genetics , Transfection , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
8.
Int J Oncol ; 11(1): 123-6, 1997 Jul.
Article in English | MEDLINE | ID: mdl-21528189

ABSTRACT

Epothilone A, a novel macrolide antibiotic, is produced by the myxobacterium Sorangium cellulosum. Similarly to paclitaxel (Taxol), epothilone A inhibits cell proliferation and induces apoptosis by binding to tubulin and stabilizing of microtubuli. Like paclitaxel, epothilone A induced apoptosis in neuroblastoma cells which exhibit constitutive cytoplasmic sequestration of p53 and, hence, an impaired DNA-damage-dependent apoptosis. However, in contrast to paclitaxel, epothilone A was also effective against a constitutively Pgp-expressing, multidrug resistant neuroblastoma cell line (SK-N-SH). Moreover, the efficacy of epothilone A was not impaired even though the Pgp level was further increased during treatment with the drug.

9.
Biochem Biophys Res Commun ; 208(1): 432-9, 1995 Mar 08.
Article in English | MEDLINE | ID: mdl-7887961

ABSTRACT

In this study, we investigated the functional role of the transcription factor AP-1 in hypoxia-induced expression of the vascular endothelial growth factor (VEGF) by using dexamethasone as an inhibitor of AP-1 activity. Phorbol ester and platelet-derived growth factor (PDGF) cause an increase in VEGF mRNA expression, which is strongly suppressed in the presence of dexamethasone, whereas hypoxia-induced VEGF expression is not inhibited by dexamethasone. Studies using a VEGF promoter luciferase construct show that the phorbol ester and PDGF-induced VEGF expression is mediated at least in part by transcriptional activation of the VEGF promoter, whereas no transcriptional activation is seen under hypoxic conditions. In contrast, hypoxia leads to an increase in VEGF mRNA stability, as confirmed by experiments using actinomycin D as an inhibitor of transcription. These results indicate that hypoxia-induced VEGF expression is independent of AP-1 mediated transcription.


Subject(s)
Endothelial Growth Factors/biosynthesis , Gene Expression , Lymphokines/biosynthesis , Transcription Factor AP-1/metabolism , Transcription, Genetic , 3T3 Cells , Animals , Becaplermin , Blotting, Northern , Cell Hypoxia , Dexamethasone/pharmacology , Humans , Kinetics , Luciferases/analysis , Luciferases/biosynthesis , Mice , Platelet-Derived Growth Factor/pharmacology , Promoter Regions, Genetic , Proto-Oncogene Proteins c-sis , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Recombinant Proteins/biosynthesis , Recombinant Proteins/pharmacology , Tetradecanoylphorbol Acetate/pharmacology , Transcription Factor AP-1/biosynthesis , Transfection , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...